Back to News
Market Impact: 0.3
MiniMed Group Q1 Earnings Call Highlights
Source: marketbeat.com
Company FundamentalsCorporate EarningsHealthcare & BiotechConsumer Demand & Retail
MiniMed Group (MMED) reported fiscal 2027 Q1 revenue of $843M, alongside 15.8% organic revenue growth. The company attributed growth to strong demand for its newer insulin-delivery and continuous glucose monitoring products, supporting performance in both the U.S. and international markets.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
MMED0.60
More News
- The IPO drought is driving private equity-owned companies to the debt market to pay investors
- CoreWeave credit default swaps hit distress levels as investors sour on AI debt
- FDA approves Enspryng for thyroid eye disease treatment
- Giant Taiwanese chipmaker TSMC confirms it’s in talks with Elon Musk to join ‘Terafab’ complex in Texas: ‘The AI market continues to be very strong’
- The Tesla Roadster 2 Is Here—and It Flies
- Suddenly, Wall Street is worried that the U.S. economy is more ‘vulnerable’ than it looks